Konstantinos Xynos is Chief Medical Officer at Replimune Group, Inc. (REPL). They have made 8 open-market trades across 1 company since 2023, most recently 2026-08-10.
CIK 0001956241
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| REPL | 224,215 | $2.4M |
Shares reported on the most recent Form 4, priced at the 2026-08-12 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| REPL | SELL | 2026-08-10 | 2026-08-12 | $12.97 | $148K | -2.9% | -14.5% | — |
| REPL | SELL | 2026-05-18 | 2026-05-20 | $5.08 | $71K | +71.1% | +115.3% | +199.8% |
| REPL | SELL | 2025-11-17 | 2025-11-19 | $9.10 | $132K | +9.2% | +7.9% | -20.7% |
| REPL | SELL | 2025-05-20 | 2025-05-22 | $8.06 | $128K | +11.3% | +6.0% | -39.7% |
| REPL | SELL | 2024-11-18 | 2024-11-20 | $10.78 | $156K | +18.0% | +12.1% | +25.9% |
| REPL | SELL · 10b5-1 | 2024-06-07 | 2024-06-10 | $7.50 | $238K | -1.6% | +0.0% | +21.9% |
| REPL | SELL | 2024-05-16 | 2024-05-20 | $6.47 | $41K | -10.1% | +34.3% | +75.4% |
| REPL | SELL | 2023-11-16 | 2023-11-17 | $10.92 | $160K | +9.4% | -29.0% | -25.0% |
| REPL | SELL | 2023-05-16 | 2023-05-18 | $18.05 | $14K | -3.7% | +19.9% | -4.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.